Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been given an average rating of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $30.10.
Separately, ValuEngine raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st.
NASDAQ:MIST traded down $0.26 during trading hours on Wednesday, reaching $17.31. The stock had a trading volume of 6,959 shares, compared to its average volume of 26,078. The stock has a 50 day moving average of $20.85. Milestone Pharmaceuticals has a 12-month low of $15.09 and a 12-month high of $27.95.
In related news, major shareholder Rtw Investments, Lp purchased 8,150 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was purchased at an average cost of $17.79 per share, with a total value of $144,988.50.
Several institutional investors have recently bought and sold shares of the company. Boxer Capital LLC bought a new position in shares of Milestone Pharmaceuticals in the second quarter worth $29,925,000. Zimmer Partners LP bought a new position in shares of Milestone Pharmaceuticals in the second quarter worth $4,344,000. Price T Rowe Associates Inc. MD bought a new position in shares of Milestone Pharmaceuticals in the second quarter worth $35,294,000. Pentwater Capital Management LP bought a new stake in Milestone Pharmaceuticals during the second quarter valued at $679,000. Finally, Novo Holdings A S bought a new stake in Milestone Pharmaceuticals during the second quarter valued at $72,612,000. 53.41% of the stock is owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Read More: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.